Recently, BASF issued a release announcing its investment in startup 3Helix Inc, with plans to jointly introduce collagen-hybridizing peptide solutions to the personal care market.
It is reported that the cooperation between the two sides involves equity investment and license agreement, BASF will get 3Helix personal care field CHP solution exclusive commercial rights, but the investment amount and specific transaction agreement has not been disclosed.
BASF said 3Helix’s patented CHP technology is based on short, single-chain collagen-like peptides, which have the unique ability to bind to damaged and denatured collagen for extraordinary anti-aging benefits. Recognizing the tremendous potential of this technology, BASF plans to bring it in-house and aims to launch a solution in 2025.
“It has been an exciting journey to bring our technology to this point where we can partner with BASF,” stated Mike Kirkness, CEO of 3Helix Inc. “We look forward to the intense collaboration in the coming years and welcome BASF to the 3Helix Board of Directors.”
“With this partnership, BASF continues to demonstrate our investment in open innovation and expand our innovative offerings to our customers,” said Dr. Marina Safont Sempere, Director of New Business Models & Digital Officer, Care Chemicals at BASF. “3Helix’s results from laboratory trials are very encouraging and show the potential of this new innovation for the personal care market.”
